PubMed Health⌕ Search

Biomedical subjects

S Hoshiya

Publications and source records attributed to S Hoshiya.

8 recordsLinked to original sources
PubMed2001

[Serological diagnosis of Helicobacter pylori infection].

H. pylori gastritis elicits both a local and a systemic immune response. Although multiple invasive tests are available for the diagnosis of H. pylori infection, serum testing for anti-H. pylori antibodies is a minimally invasive test available to diagnose this infection. Latex agglutination is available, but most kits use ELISA. The sensitivities and specificities of many commercial kits were more than 90%. However, most of these serologic detection kits were made in Western countries. There might been the influence of geographical differences on test results. Recently, serological test has been reported about of usefulness in monitoring after eradication therapy at long-term period.

Antibodies, Bacterial↗
PubMed2000

Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.

Since clarithromycin is expected to be widely used to treat Helicobacter pylori infection in the near future, it is important to investigate the relationship between resistance to clarithromycin and the regimens of eradication therapy. We investigated: (1) the usefulness of susceptibility tests prior to eradication therapy, and (2) the rate of acquisition of H. pylori resistance to clarithromycin after treatment failure. Drug susceptibility tests to clarithromycin and amoxicillin were conducted by Dry Plate Test or E-test. The subjects in the first part of this study included 112 patients with H. pylori infection who received triple therapy with various combinations of drugs, including clarithromycin. The eradication rate in patients with clarithromycin-susceptible H. pylori was significantly higher than that in patients with clarithromycin-resistant H. pylori. The second part of this study included 21 patients in whom H. pylori was not eradicated by triple therapy and 12 patients in whom H. pylori was not eradicated with dual therapy including clarithromycin. Of the 33 patients showing non-eradication. 90.9% of those treated with dual therapy and 35.7% of those treated with triple therapy acquired secondary resistance of H. pylori to clarithromycin. We conclude that it is important to conduct drug susceptibility tests prior to treatment of H. pylori infection. Since the incidence of acquiring clarithromycin resistance was significantly higher in the patients showing non-eradication, it is important to choose a regimen with a higher eradication rate, such as triple therapy.

2-Pyridinylmethylsulfinylbenzimidazoles↗
PubMed2000

[A study on the appropriate time point for the assessment of Helicobacter pylori eradication--evaluation from the re-positive rate of H. pylori after successful eradication and delayed decrease of 13C-urea breath test levels].

We attempted to evaluate the appropriate time point for the assessment of Helicobacter pylori eradication after treatment. One hundred and nine patients with gastroduodenal diseases were enrolled this study. All of them were received proton pomp inhibitor based triple therapy and diagnosed as eradication of H. pylori infection at initial assessment. They were followed up over six months. The diagnosis of H. pylori eradication was determined by rapid urease test, culture, histology and 13C-urea breath test (UBT), and the initial assessment of the eradication was performed on 31-90 days after finishing eradication therapy. Re-appearance rate of H. pylori after initial diagnosis of eradication was 4.6% (5/109), and the mean follow-up period of them was 16.3 months. The time period of initial assessment of eradication in these 5 patients were 35, 37, 42, 49 and 60 days after treatment, respectively. On the other hand, there were 6 patients who were diagnosed as failed of eradication therapy by 13C-UBT, and being success at following period. All of the 13C-UBT levels of these 6 patients were less than 10/1000 and were decreased within negative range subsequently. The time periods of initial diagnosis of these patients except one were within 2 months after treatment. It was concluded that the assessment time of H. pylori eradication should be performed over 2 months after eradication therapy.

Adult↗
PubMed1999

[Evaluation of CO2 condition for antibiotic susceptibility test of Helicobacter pylori on microdilution broth].

We determined the MICs of clarithromycin for 32 Helicobacter pylori strains isolated from gastric mucosa of patients, by using microdilution broth method under different microaerobic conditions (CO2: 5% and 15%). The pH of broth was more acidic at 15% CO2 than that of at 5% CO2. The MICs of clarithromycin for all H. pylori strains at 15% CO2 condition were higher than that of clarithromycin at 5% CO2 condition. Comparing the MICs with the results of eradication therapy, we concluded that the measurement of MIC under 5%CO2 condition is more useful for expecting the clinical outcome.

Carbon Dioxide↗
PubMed1999

[The treatment strategy of H. pylori infection and the new triple therapy].

The strategies against H. pylori infection have been developed very fast. Since the efficacy of mono-therapy (one antimicrobial drug) and dual-therapy (proton-pump inhibitor (PPI) + one antimicrobial drug) were not good, and the safety of classical triple therapy (bismuth + two antimicrobial drugs) was bad, new triple-therapy consisted with PPI + two antimicrobial drugs is considered as a standard regimen of the treatment of H. pylori infection. However there are several questions about this new strategy which we have to answer. The first question is how can we diagnose the cure of H. pylori infection and when we should do it? The second one is which statistical method should we choose for evaluating the success rate? The third one is which drug should we use and how long should the patient continuing to have the drug? A lot of scientific research are need to clarify these questions.

Anti-Bacterial Agents↗